SAMD4A Antibody

What is SAMD4A and what distinguishes it from other SAMD4 family members?

SAMD4A (Sterile Alpha Motif Domain-containing protein 4A) is a RNA-binding protein belonging to the SAMD4 protein family, which is highly conserved from yeast to humans. In mammals, this family includes two members: SAMD4A (also known as Smaug1) and SAMD4B (Smaug2) . The primary distinguishing feature between these proteins is that SAMD4A is an interferon-stimulated gene (ISG), while SAMD4B, despite having similar functions, is not regulated by interferons . Both proteins contain a conserved SAM domain that enables specific binding to stem-loop structures called Smaug Recognition Elements (SREs) in target mRNAs .

SAMD4A functions primarily as a post-transcriptional regulator and translational repressor, though recent research has revealed it can also promote translation of certain mRNAs . It can form cytoplasmic mRNA silencing foci in neurons and cytosolic membrane-less organelles termed "Smaug1 bodies" that regulate mitochondrial function . The mouse genome encodes a single Samd4 protein that functionally resembles both human SAMD4A and SAMD4B .

Methodologically, when studying SAMD4 family members, researchers should carefully choose antibodies that specifically distinguish between SAMD4A and SAMD4B to avoid cross-reactivity, particularly when examining interferon-mediated responses.

What are the characterized functional domains of SAMD4A and how do they contribute to its biological activity?

SAMD4A contains several functional domains that are critical for its biological activities:

• SAM (Sterile Alpha Motif) Domain: The most well-characterized domain, which specifically binds to SRE-containing mRNAs. This domain is essential for RNA recognition and binding, as demonstrated in studies of HBV inhibition where the SAM domain specifically binds to conserved SRE-like sites in HBV RNA to trigger viral RNA degradation .

• C-Terminal Domain: Required for SAMD4A's anti-HBV function, as demonstrated in structure-function studies showing that the C-terminal domain is necessary for complete suppression of viral replication .

• 14-3-3 Binding Motifs: SAMD4A contains two putative 14-3-3 binding motifs that conform to the mode I motif (RSV(pS)LT, aa 251–265; KTR(pS)LP, aa 655–660). These sites mediate interaction with 14-3-3 proteins, which may link SAMD4A to the mTORC1 signaling pathway .

To study domain-specific functions, researchers can employ:

• Deletion mutants targeting specific domains

• Point mutations in critical residues (e.g., the H86P mutation in the mouse Samd4 SAM domain affects 14-3-3 protein binding )

• Domain-swapping experiments between SAMD4A and related proteins

These approaches, combined with appropriate antibodies recognizing different regions of SAMD4A, allow for comprehensive functional analysis of domain-specific contributions to SAMD4A activity.

What cellular and subcellular localization patterns does SAMD4A exhibit during different biological processes?

SAMD4A exhibits dynamic localization patterns that correlate with its diverse biological functions:

• Cytoplasmic mRNA Silencing Foci: SAMD4A localizes to distinct cytoplasmic foci where it participates in mRNA silencing, particularly in neurons. These foci are sites where SAMD4A regulates the translation of SRE-containing mRNAs .

• Smaug1 Bodies: SAMD4A forms cytosolic membrane-less organelles (MLOs) termed "Smaug1 bodies" that regulate mitochondrial function. These structures represent a specialized subcellular compartmentalization of SAMD4A activity .

• Hepatocellular Localization: During viral infection, SAMD4A localizes to hepatocytes where it functions as an interferon-stimulated gene to inhibit HBV replication by binding to viral RNA .

• Developmental Localization: During cardiac development, SAMD4A shows increased expression in early heart development stages and is particularly enriched in ventricular cardiomyocytes .

For accurate visualization of SAMD4A localization, researchers should:

• Use validated SAMD4A antibodies (such as the rabbit polyclonal antibody ab254693 which has been validated for ICC/IF and IHC-P applications )

• Employ proper fixation methods (PFA fixation with Triton X-100 permeabilization has been successfully used for SAMD4A immunostaining in CACO-2 cells )

• Consider co-staining with organelle markers to precisely define subcellular localization

• Implement time-course studies to capture dynamic changes in localization during biological processes

What criteria should researchers consider when selecting an appropriate SAMD4A antibody for specific experimental applications?

When selecting a SAMD4A antibody, researchers should consider the following criteria:

• Target Epitope Location: Determine whether the antibody targets the SAM domain, C-terminal domain, or other regions of SAMD4A. For functional studies, antibodies targeting the SAM domain (aa 1-200) may be particularly informative as this region is critical for RNA binding. The antibody described in search result targets the region within aa 550-650, which is in the C-terminal portion of the protein.

• Validated Applications: Confirm that the antibody has been validated for your specific application:

  • For protein localization: ICC/IF or IHC-P

  • For protein quantification: Western blot

  • For protein-protein interactions: IP/Co-IP

  • For ChIP-seq applications: ChIP-grade antibodies

• Species Reactivity: Ensure the antibody recognizes SAMD4A from your experimental species. Many commercially available antibodies are validated for human SAMD4A but may cross-react with mouse Samd4 due to sequence homology .

• Specificity for SAMD4A vs. SAMD4B: Given the sequence similarity between SAMD4A and SAMD4B, verify that the antibody specifically recognizes SAMD4A without cross-reactivity to SAMD4B, especially in studies investigating interferon-mediated responses where SAMD4A-specific detection is crucial .

• Monoclonal vs. Polyclonal: Consider the trade-offs:

  • Polyclonal antibodies (like ab254693 ) typically offer higher sensitivity but may have more background

  • Monoclonal antibodies provide higher specificity but potentially lower sensitivity

For validation, researchers should include:

• Positive control tissues known to express SAMD4A (e.g., testis )

• Negative controls (SAMD4A knockout/knockdown samples)

• Peptide competition assays to confirm specificity

How can researchers validate the specificity of SAMD4A antibodies in their experimental systems?

Thorough validation of SAMD4A antibodies is essential for reliable experimental results. Researchers should implement the following validation strategies:

• Genetic Knockdown/Knockout Controls:

  • Generate SAMD4A knockdown using siRNA or shRNA approaches as demonstrated in cardiomyocyte differentiation studies

  • Utilize CRISPR/Cas9 to create SAMD4A knockout cell lines

  • Test antibody reactivity in these systems to confirm signal loss or reduction

• Recombinant Protein Controls:

  • Express tagged recombinant SAMD4A (with Flag, HA, or other epitope tags)

  • Perform parallel detection with anti-tag antibody and SAMD4A antibody

  • Signals should colocalize or show similar patterns in Western blots

• Cross-Reactivity Assessment:

  • Test antibody against both SAMD4A and SAMD4B recombinant proteins

  • Perform Western blots in tissues known to express either SAMD4A or SAMD4B predominantly

  • For mouse studies, determine whether the antibody cross-reacts with mouse Samd4

• Peptide Competition Assays:

  • Pre-incubate antibody with the immunizing peptide (for ab254693, a peptide from aa 550-650 )

  • Apply to Western blot or immunostaining in parallel with untreated antibody

  • Specific signals should be blocked by peptide competition

• Correlation of Protein with mRNA Expression:

  • Compare antibody staining patterns with mRNA expression data (RT-qPCR or RNA-seq)

  • In developmental or disease models, protein expression changes should correlate with transcriptional changes

For immunohistochemical applications specifically, researchers should validate by:

• Testing multiple fixation protocols (the data indicates PFA fixation works well for SAMD4A )

• Confirming expected tissue distribution (e.g., testis samples show positive staining at 1/2500 dilution )

• Comparing staining patterns across multiple antibodies targeting different SAMD4A epitopes

What are the optimal conditions and protocols for immunodetection of SAMD4A in different sample types?

Based on the available research data, the following optimized protocols are recommended for SAMD4A immunodetection:

For Immunocytochemistry/Immunofluorescence (ICC/IF):

• Fixation: 4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature

• Permeabilization: 0.1% Triton X-100 in PBS for 10 minutes

• Blocking: 5% normal serum (from the species of secondary antibody) with 1% BSA in PBS for 1 hour

• Primary antibody: Apply rabbit polyclonal SAMD4A antibody at 4μg/ml concentration in blocking buffer

• Incubation: Overnight at 4°C

• Secondary antibody: Anti-rabbit fluorescent-conjugated secondary antibody (1:500)

• Counterstain: DAPI for nuclear visualization

• Mounting: Anti-fade mounting medium

For Immunohistochemistry on Paraffin Sections (IHC-P):

• Deparaffinization: Standard xylene and ethanol series

• Antigen retrieval: Citrate buffer (pH 6.0) at 95°C for 20 minutes

• Peroxidase blocking: 3% hydrogen peroxide for 10 minutes

• Protein blocking: 5% normal serum in PBS for 1 hour

• Primary antibody: SAMD4A antibody at 1/2500 dilution

• Incubation: Overnight at 4°C

• Detection: HRP-conjugated secondary antibody and DAB substrate

• Counterstain: Hematoxylin

For Western Blot:

• Sample preparation: RIPA buffer with protease inhibitors

• Protein loading: 20-40 μg total protein per lane

• Transfer: PVDF membrane (0.45 μm pore size)

• Blocking: 5% non-fat dry milk in TBST for 1 hour

• Primary antibody: SAMD4A antibody at optimal dilution (typically 1:1000)

• Incubation: Overnight at 4°C

• Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000)

• Detection: Enhanced chemiluminescence (ECL)

For Co-Immunoprecipitation (based on Samd4 interaction studies ):

• Cell lysis: NP-40 buffer with protease and phosphatase inhibitors

• Pre-clearing: Protein A/G beads for 1 hour

• Immunoprecipitation: SAMD4A antibody (5 μg) or Flag antibody for tagged constructs

• Incubation: Overnight at 4°C with rotation

• Washing: 4-5 times with lysis buffer

• Elution: Laemmli buffer at

• Analysis: Western blotting for interacting proteins

How can researchers effectively study SAMD4A's RNA-binding properties and identify its target RNAs?

To investigate SAMD4A's RNA-binding properties and identify its target RNAs, researchers can employ the following methodological approaches:

• RNA Immunoprecipitation (RIP) Assay:

  • Cross-link RNA-protein complexes in cultured cells

  • Lyse cells and immunoprecipitate with SAMD4A antibody

  • Extract and purify bound RNAs

  • Analyze by RT-qPCR for specific targets or RNA-seq for global analysis

  • This approach was used to identify FGF2 mRNA as a binding target of SAMD4A in cardiac development

• Electrophoretic Mobility Shift Assay (EMSA):

  • Generate purified recombinant SAMD4A protein (focusing on the SAM domain)

  • Synthesize labeled RNA probes containing putative SRE motifs

  • Incubate protein with RNA and analyze binding by gel shift

  • Include competition assays with unlabeled RNA to confirm specificity

  • This approach helped identify the CNGG/CNGGN motif as the SAMD4A binding site

• CLIP-seq (Cross-linking Immunoprecipitation followed by sequencing):

  • UV cross-link RNA-protein complexes in vivo

  • Immunoprecipitate with SAMD4A antibody

  • Process samples for high-throughput sequencing

  • Analyze binding motifs using computational tools

  • This approach can identify genome-wide SAMD4A binding sites

• Luciferase Reporter Assays for SRE Functionality:

  • Clone potential SRE-containing 3'UTR sequences downstream of luciferase

  • Co-transfect with SAMD4A expression constructs

  • Measure luciferase activity to assess SAMD4A-mediated regulation

  • Include SRE mutant constructs as controls

  • This method was used to validate the functional impact of SAMD4A binding to HBV RNA

• Structure-Function Analysis of RNA-Protein Interactions:

  • Generate SAMD4A deletion or point mutations affecting the SAM domain

  • Compare wild-type and mutant SAMD4A binding to target RNAs

  • Utilize the H86P mutation in the mouse Samd4 SAM domain as a model for disrupted RNA binding

  • Correlate binding defects with functional outcomes

For identifying novel SAMD4A target RNAs, researchers should:

• Perform RIP-seq or CLIP-seq

• Search for the CNGG/CNGGN motif in the resulting sequences

• Validate candidate targets using reporter assays and functional studies

• Consider the biological context, as SAMD4A may have tissue-specific targets

How can SAMD4A antibodies be utilized to investigate its role in viral inhibition mechanisms, particularly against HBV?

SAMD4A antibodies are valuable tools for investigating its antiviral mechanisms against HBV through several advanced research approaches:

• Monitoring SAMD4A Induction During Interferon Treatment:

  • Treat cells or tissues with IFN-α at different time points

  • Use SAMD4A antibodies for Western blot or immunofluorescence to quantify protein induction

  • Correlate SAMD4A levels with HBV suppression

  • This approach can validate SAMD4A as a key mediator of IFN-α's anti-HBV effect

• Visualization of SAMD4A-HBV RNA Interactions in situ:

  • Perform RNA-protein double labeling using SAMD4A antibodies and fluorescent probes for HBV RNA

  • Apply proximity ligation assay (PLA) to detect direct interactions

  • Use super-resolution microscopy to visualize co-localization in subcellular compartments

  • This allows direct visualization of SAMD4A's interaction with viral RNA in living cells

• Analysis of SAMD4A-Containing Antiviral Complexes:

  • Immunoprecipitate SAMD4A from HBV-infected cells

  • Identify co-precipitating proteins by mass spectrometry

  • Validate interactions with co-immunoprecipitation using SAMD4A antibodies

  • This approach can reveal the complete antiviral complex formed around SAMD4A

• Investigating SAMD4A Dynamics During HBV Infection:

  • Use time-course analysis with SAMD4A antibodies in HBV-infected hepatocytes

  • Correlate subcellular localization changes with phases of viral replication

  • Perform live-cell imaging with fluorescently tagged SAMD4A to track its dynamics

  • This provides insights into the temporal aspects of SAMD4A's antiviral activity

• Therapeutic Applications in Animal Models:

  • Deliver AAV-SAMD4A to HBV-producing transgenic mice

  • Use SAMD4A antibodies to confirm protein expression in liver tissue

  • Correlate expression levels with reduction in virus titers

  • This approach has been validated in studies showing that AAV-delivered SAMD4A expression reduced HBV titers in transgenic mice

• Clinical Correlation Studies:

  • Analyze SAMD4A protein levels in liver biopsies from HBV patients

  • Correlate expression with viral load and treatment response

  • Stratify patients based on SAMD4A levels to predict IFN therapy effectiveness

  • This is supported by database analyses showing negative correlation between SAMD4A/B levels and HBV in patients

Table 1: Experimental Design for Investigating SAMD4A's Anti-HBV Activity

What role does SAMD4A play in cardiac development and how can antibody-based approaches help elucidate its function?

Recent research has revealed a critical role for SAMD4A in cardiac development through its regulation of FGF2 expression . SAMD4A antibodies can be instrumental in elucidating these mechanisms through the following approaches:

• Developmental Expression Profiling:

  • Perform immunohistochemistry on embryonic heart sections at different developmental stages

  • Use SAMD4A antibodies to track protein expression patterns spatiotemporally

  • Correlate with cardiac differentiation markers to establish developmental relevance

  • This approach revealed increased SAMD4A expression during early heart development

• Subcellular Localization During Cardiomyocyte Differentiation:

  • Apply immunofluorescence with SAMD4A antibodies to track protein localization

  • Use confocal microscopy to monitor changes during hESC differentiation to cardiomyocytes

  • Co-stain with RNA processing markers to identify functional complexes

  • This can reveal dynamic changes in SAMD4A localization during cardiac specification

• Protein-RNA Interaction Analysis in Cardiac Context:

  • Perform RNA immunoprecipitation using SAMD4A antibodies in cardiomyocytes

  • Identify bound mRNAs (particularly FGF2) by RT-qPCR or sequencing

  • Validate binding specificities using SAMD4A knockdown controls

  • This approach identified FGF2 mRNA as a critical SAMD4A target in cardiac development

• Signaling Pathway Investigation:

  • Use SAMD4A antibodies alongside phospho-specific antibodies for AKT pathway components

  • Perform Western blot analysis in SAMD4A knockdown/overexpression models

  • Correlate SAMD4A levels with AKT pathway activation

  • This revealed that SAMD4A regulates the AKT signaling pathway through FGF2 during cardiomyogenesis

• Clinical Correlation in Congenital Heart Disease (CHD):

  • Analyze SAMD4A expression in human CHD samples using immunohistochemistry

  • Correlate expression patterns with disease subtypes and severity

  • This is supported by single-cell sequencing data showing decreased SAMD4A expression in cardiomyocytes from CHD patients

• Protein-Protein Interaction Networks:

  • Immunoprecipitate SAMD4A from cardiac cells at different differentiation stages

  • Identify co-precipitating proteins by mass spectrometry

  • Validate interactions with co-immunoprecipitation and antibodies against putative partners

  • This approach can reveal stage-specific interaction partners during cardiomyogenesis

Table 2: SAMD4A Expression and Function During Cardiac Development Stages

How can researchers investigate the contradictory roles of SAMD4A in different types of cancer?

SAMD4A exhibits context-dependent roles in cancer, acting as a tumor suppressor in breast cancer while showing high expression in ovarian cancer . Researchers can use antibody-based approaches to investigate these contradictory roles:

• Comprehensive Expression Profiling Across Cancer Types:

  • Perform immunohistochemistry using SAMD4A antibodies on tissue microarrays spanning multiple cancer types

  • Quantify expression levels and correlate with clinical parameters

  • Compare expression in matched tumor and adjacent normal tissues

  • This approach revealed decreased SAMD4A expression in breast cancer versus increased expression in ovarian cancer

• Mechanistic Investigation of Tumor-Specific Functions:

  • In breast cancer: Use SAMD4A antibodies to analyze binding to proangiogenic mRNAs

    • Perform RNA immunoprecipitation followed by qPCR for CXCL5, ENG, IL1β, and ANGPT1

    • Correlate binding with mRNA stability and protein expression

    • This revealed SAMD4A's role in destabilizing proangiogenic mRNAs in breast cancer

  • In ovarian cancer: Investigate alternative RNA targets or protein interactions

    • Identify cancer-specific SAMD4A interactome through immunoprecipitation

    • Compare RNA binding profiles between cancer types

    • This may reveal context-dependent regulation of different target mRNAs

• Analysis of Post-Translational Modifications:

  • Use phospho-specific antibodies alongside SAMD4A antibodies

  • Investigate whether cancer-specific phosphorylation affects SAMD4A function

  • Compare phosphorylation patterns across cancer types

  • This is supported by findings of SAMD4A interaction with 14-3-3 proteins through phosphorylated residues

• Investigation of Subcellular Localization Differences:

  • Apply immunofluorescence to analyze SAMD4A localization in different cancer cells

  • Determine whether functional differences correlate with altered localization

  • Co-stain with markers for RNA processing bodies or stress granules

  • This may reveal cancer-specific compartmentalization of SAMD4A activity

• Correlation with Genetic Alterations:

  • Perform SNP analysis of SAMD4A in different cancers

  • Use antibodies to correlate protein expression with specific genetic variants

  • This is supported by findings that SAMD4A SNP rs1957358 affects oral cancer risk

Table 3: Contradictory Roles of SAMD4A in Different Cancer Types

What are common technical challenges when using SAMD4A antibodies and how can researchers overcome them?

Researchers working with SAMD4A antibodies may encounter several technical challenges. The following troubleshooting strategies address common issues:

• High Background in Immunostaining:

  • Cause: Non-specific binding, excessive antibody concentration, inadequate blocking

  • Solution:

    • Increase blocking time and concentration (5-10% normal serum)

    • Optimize antibody dilution (starting with 1/2500 for IHC-P as validated )

    • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific binding

    • Pre-absorb antibody with tissue powder from species being tested

    • Use more stringent washing steps (increase number and duration)

• Weak or Absent Signal:

  • Cause: Inadequate antigen retrieval, low expression, epitope masking, antibody degradation

  • Solution:

    • Optimize antigen retrieval (test citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

    • Extend primary antibody incubation time (overnight at 4°C)

    • Use signal amplification systems (e.g., tyramide signal amplification)

    • Confirm SAMD4A expression in your sample type by RT-qPCR

    • Check antibody storage conditions and avoid repeated freeze-thaw cycles

• Cross-Reactivity with SAMD4B:

  • Cause: Sequence similarity between SAMD4A and SAMD4B

  • Solution:

    • Validate antibody specificity using recombinant SAMD4A and SAMD4B proteins

    • Include SAMD4A knockdown controls

    • Use antibodies targeting unique regions outside conserved SAM domains

    • Perform parallel detection with SAMD4A-specific and SAMD4B-specific antibodies

• Inconsistent Results in Co-IP Experiments:

  • Cause: Weak or transient protein interactions, inappropriate buffer conditions

  • Solution:

    • Use cross-linking reagents to stabilize protein-protein interactions

    • Optimize lysis buffer conditions (test different detergents and salt concentrations)

    • Consider native PAGE instead of denaturing conditions

    • Include phosphatase inhibitors to preserve 14-3-3 binding

    • Use tagged SAMD4A constructs for improved pulldown efficiency

• Variable Results in RNA-IP Experiments:

  • Cause: RNA degradation, inefficient crosslinking, non-specific binding

  • Solution:

    • Use RNase inhibitors throughout the procedure

    • Optimize UV crosslinking time for RNA-protein complexes

    • Include negative controls (IgG, non-target RNA)

    • Validate results with multiple primer sets for target RNAs

    • Consider CLIP approaches for increased specificity

Table 4: Troubleshooting Guide for Common SAMD4A Antibody Issues

How might SAMD4A antibodies contribute to understanding its role in myopathy and metabolic disorders?

SAMD4A has been implicated in myopathy and metabolic regulation, particularly through a missense mutation in mouse Samd4 that results in leanness, myopathy, and uncoupled mitochondrial respiration . SAMD4A antibodies can facilitate research in this emerging area through:

• Structural and Functional Analysis of Mutant SAMD4A:

  • Compare wild-type and mutant SAMD4A localization in muscle cells using immunofluorescence

  • Analyze how mutations affect SAMD4A's interaction with 14-3-3 proteins by co-immunoprecipitation

  • Investigate phosphorylation status using phospho-specific antibodies

  • This approach revealed that the H86P mutation in mouse Samd4 affects interaction with 14-3-3 proteins

• Investigation of SAMD4A's Role in mTORC1 Signaling:

  • Use SAMD4A antibodies alongside mTORC1 pathway component antibodies

  • Perform immunoprecipitation to isolate SAMD4A-containing complexes from muscle tissue

  • Analyze phosphorylation-dependent interactions with 14-3-3 proteins

  • This can help elucidate how SAMD4A connects to mTORC1 signaling through 14-3-3 proteins and Akt phosphorylation

• Analysis of SAMD4A in Mitochondrial Regulation:

  • Co-localize SAMD4A with mitochondrial markers using immunofluorescence

  • Investigate SAMD4A's presence in mitochondria-associated membranes

  • Correlate SAMD4A expression with markers of mitochondrial function

  • This approach can reveal how SAMD4A influences mitochondrial respiration in muscle cells

• Therapeutic Target Validation:

  • Use SAMD4A antibodies to monitor protein levels in response to potential therapeutic compounds

  • Screen for molecules that modulate SAMD4A's interaction with 14-3-3 proteins

  • Validate target engagement in muscle tissue using immunohistochemistry

  • This may lead to novel therapeutic approaches for myopathy

• Clinical Correlation Studies:

  • Analyze SAMD4A expression and localization in muscle biopsies from myopathy patients

  • Correlate expression patterns with disease subtypes and severity

  • Investigate genetic variants and their effect on protein expression and function

The research into SAMD4A's role in myopathy is particularly interesting as it connects RNA-binding function with metabolic regulation through mTORC1 signaling. Future studies should address whether SAMD4A regulates translation of specific mRNAs involved in muscle metabolism and how its dysfunction leads to the uncoupling of mitochondrial respiration.